CD8A and neoplasm: Since cytotoxic CD8 T-cells are key immune effectors that eradicate malignant cells, a prerequisite for cancer immunotherapy is to activate and expand tumor-reactive CD8 T-cells capable of recognizing and destroying tumor cells [1, 2].